We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-19.99%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$887M
AUM Growth
+$16.2M
Cap. Flow
+$129M
Cap. Flow %
14.54%
Top 10 Hldgs %
50.79%
Holding
136
New
23
Increased
31
Reduced
31
Closed
36

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$34.3M
2
AZN icon
AstraZeneca
AZN
+$20.1M
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$14.8M
4
VTRS icon
Viatris
VTRS
+$11.4M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$10.3M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$44.9M
2
MRK icon
Merck
MRK
+$22.8M
3
GSK icon
GSK
GSK
+$21.9M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.53M
5
V icon
Visa
V
+$6.06M

Sector Composition

Rank Sector Weight
1 Healthcare 60.28%
2 Technology 12.21%
3 Industrials 2.92%
4 Consumer Discretionary 0.53%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVRD
51
Tvardi Therapeutics
TVRD
$19.7M
$3.95M 0.45%
8,443
+1,334
+19% +$861K
SGMO
52
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$3.9M 0.44%
+340,000
New +$4.22M
STRO icon
53
Sutro Biopharma
STRO
$401M
$3.68M 0.41%
40,789
+13,289
+48% +$1.6M
ASND icon
54
Ascendis Pharma A/S
ASND
$16B
$3.65M 0.41%
58,273
-34,400
-37% -$2.16M
NEOS
55
DELISTED
Neos Therapeutics, Inc
NEOS
$3.63M 0.41%
2,201,697
+1,370,000
+165% +$3.84M
KRYS icon
56
Krystal Biotech
KRYS
$10.1B
$3.63M 0.41%
+174,625
New +$3.66M
QTTB icon
57
Q32 Bio
QTTB
$466M
$3.6M 0.41%
8,944
-4,673
-34% -$1.77M
EVOK
58
DELISTED
Evoke Pharma
EVOK
$3.5M 0.39%
9,798
– –
ARVN icon
59
Arvinas
ARVN
$518M
$3.48M 0.39%
271,053
+31,053
+13% +$493K
XBI icon
60
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$3.23M 0.36%
+45,000
New +$3.63M
AGIO icon
61
Agios Pharmaceuticals
AGIO
$1.79B
$3.11M 0.35%
+67,500
New +$4.17M
KDMN
62
DELISTED
Kadmon Holdings, Inc.
KDMN
$3.1M 0.35%
1,490,000
– –
ALLO icon
63
Allogene Therapeutics
ALLO
$649M
$3.06M 0.34%
+113,437
New +$3.01M
ACIU icon
64
AC Immune
ACIU
$223M
$2.94M 0.33%
310,613
-192,950
-38% -$1.82M
PTLA
65
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$2.87M 0.32%
147,000
– –
XENE icon
66
Xenon Pharmaceuticals
XENE
$6.06B
$2.84M 0.32%
449,484
+70,000
+18% +$622K
DCPH
67
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$2.42M 0.27%
115,033
+5,000
+5% +$123K
CBIO
68
Crescent Biopharma
CBIO
$537M
$2.38M 0.27%
2,510
– –
SAGE
69
PUT
DELISTED
Sage Therapeutics
SAGE
$2.35M 0.26%
+24,500
New +$2.8M
TBIO
70
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$2.32M 0.26%
309,400
+32,761
+12% +$240K
VTGN icon
71
VistaGen Therapeutics
VTGN
$9.89M
$2.21M 0.25%
49,131
-6,666
-12% -$363K
KRNT icon
72
Kornit Digital
KRNT
$705M
$2.12M 0.24%
+30,342
New +$594K
IMTX icon
73
Immatics
IMTX
$1.18B
$2.05M 0.23%
+200,000
New +$1.94M
ABEO icon
74
Abeona Therapeutics
ABEO
$366M
$1.93M 0.22%
10,801
-2,677
-20% -$584K
WHWK
75
Whitehawk Therapeutics
WHWK
$190M
$1.92M 0.22%
75,455
– –
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2018 Portfolio in Review

As of Q4 2018, Sphera Funds Management held 136 positions worth $887M, up 1.9% from $871M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Sphera Funds Management deployed $129M of net new capital in Q4 2018, opening 23 new positions and adding to 31 existing holdings. Its largest new stake was Celgene Corp: 465,000 shares worth $29.8M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 75% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Merck, an estimated $22.8M trimmed.

  • Sphera Funds Management's largest Q4 2018 buy was Celgene Corp: 465,000 shares worth $29.8M.
  • Sphera Funds Management added most to Viatris in Q4 2018, an estimated $11.4M increase.
  • Sphera Funds Management's biggest Q4 2018 reduction was Merck, cutting an estimated $22.8M.
  • Sphera Funds Management fully exited Johnson & Johnson in Q4 2018, selling an estimated $44.9M.
  • Sphera Funds Management's ten largest holdings make up 51% of its $887M portfolio in Q4 2018.
  • Sphera Funds Management opened 23 new positions and closed 36 in Q4 2018.
  • Sphera Funds Management's portfolio value rose 1.9% quarter-over-quarter to $887M.

Based on Sphera Funds Management's 13F filing for Q4 2018, filed 14 Feb 2019.